Navigation Links
Potential new drug for some patients with treatment-resistant lung cancer
Date:10/20/2013

BOSTON The investigational drug AZD9291, a third-generation EGFR inhibitor, showed promise in preclinical studies and provides hope for patients with advanced lung cancers that have become resistant to existing EGFR inhibitors, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

Mutations in the growth factor gene EGFR are present in about 10 to 15 percent of patients with the most common form of lung cancer, non-small cell lung cancer (NSCLC). Most NSCLCs harboring these EGFR mutations, called activating mutations, respond to the EGFR inhibitor drugs erlotinib and gefitinib. A majority of such cancers, however, develop resistance to these drugs within about nine to 11 months. In many cases, this is due to the cancer cells acquiring a second mutation called EGFR T790M, also known as the "resistance mutation."

"There are no approved therapies to treat lung cancer patients who develop the second mutation in the EGFR that stops the currently available medicines from working," said Susan Galbraith, M.D., Ph.D., head of the Oncology Innovative Medicines Unit at AstraZeneca. "The innovative breakthrough was finding a series of molecules that could target both the activating and resistance mutant forms of EGFR more potently than normal EGFR, which led to development of the new EGFR kinase inhibitor, AZD9291.

"AZD9291 is highly active in preclinical models and is well tolerated in animal models. It inhibits both activating and resistant EGFR mutations while sparing the normal form of EGFR that is present in normal skin and gut cells, thereby reducing the side effects encountered with currently available medicines," she added.

The AstraZeneca scientists first showed that AZD9291 potently inhibited lung cancer cells with mutant EGFR, grown in lab dishes. They then tested the drug on mice bearing lung tumors with activating mutations and mice bearing lung tumors with resistance mutations. AZD9291 showed substantial tumor shrinkage in both groups of mice after 14 days of treatment. After 40 days, the researchers found no visible tumors in these mice, and this effect was sustained for more than 100 days. They also observed similar tumor shrinkage in mice that were genetically modified to develop tumors bearing both the activating and resistance mutations.

When the investigators analyzed blood samples collected from the treated mice, they identified a breakdown product of the parent compound AZD9291, which they called AZ5104, circulating in blood in addition to AZD9291. They then found that AZ5104 is also a potent inhibitor of activating and resistance EGFR mutations, and speculated that this may contribute to the efficacy seen after dosing with AZD9291.

Using data from blood analyses of mice, the researchers then developed a mathematical model to evaluate the dynamics of conversion of AZD9291 to AZ5104 and cumulative tumor-inhibitory effects. These experiments helped them determine the potentially effective doses of AZD9291 for patients with NSCLC harboring both activating and resistance EGFR mutations.

"Findings from preclinical studies have recently been translated to the clinic, where the drug has already demonstrated tumor shrinkage in patients and has been well tolerated, with low rates of side effects," said Galbraith. "The degree of response to treatment with AZD9291 in such a short period of time is very exciting. This new drug has the potential to provide new treatment options for patients in this setting."


'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Related medicine news :

1. Study identifies potential treatment for lethal childhood leukemia
2. McMaster researchers find potential for new uses of old drug
3. Army researcher develops potential vaccine carrier
4. UNC study shows potential to revive abandoned cancer drug by nanoparticle drug delivery
5. New study of NIH funding allocations suggests potential efficiency gains
6. A closer look at PARP-1 reveals potential new drug targets
7. Hybrid vaccine demonstrates potential to prevent breast cancer recurrence
8. VCU Massey Cancer Center sees potential in novel leukemia treatment
9. Misuse of over-the-counter pain medication is potential health threat
10. Mutations in JAK3 gene identified in subtype of lymphoma provide potential drug target
11. Bioinformatics experts at the CNIO explore additional coding potential hidden in the human genome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Colorado (PRWEB) , ... February 11, 2016 , ... Colorado ... Review as one of 334 spine surgeons to know in 2016 . The ... in the field of spine surgery. , Dr. Corenman understands the importance of ...
(Date:2/11/2016)... ... February 11, 2016 , ... Talix today announced ... , will be presenting at the 2016 HIMSS Annual Conference & Exhibition, taking ... During his session, “ Coding for Care: Using Data Analytics for Risk Adjustment ...
(Date:2/11/2016)... Rock, AR (PRWEB) , ... February 11, 2016 , ... ... in their community by announcing a new fundraiser in support of a local boy ... also hopes the campaign will bring awareness to, and rally support for, all local ...
(Date:2/11/2016)... ... February 11, 2016 , ... Pixel Film Studios brings the spirit of the ... the Christmas edition of the ProDrop series. Pick and choose from 30 unique designs ... spirit of Christmas using ProDrop's wintry generators. ProDrop Christmas is a Final Cut Pro ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... exhibiting at the American Academy of Dermatology Annual Meeting at the Walter E. ... is to raise awareness for both the condition of hyperhidrosis (excessive sweating) and ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... 11, 2016 Jeffrey Zucker , ... Trials, will present at this year,s Summit for Clinical Operations ... in Miami, FL. Zucker will discuss ... study execution, supporting SCOPE,s "Improving Site Study Activation and Performance" ... Thursday, Feb. 25 at 11:05 a.m. --> ...
(Date:2/11/2016)... , Feb. 11, 2016  Delcath Systems, Inc. ... medical device company focused on oncology with an ... liver cancers, announces the engagement of Lars ... Global Medical Consultant. Dr. Birgerson will provide strategic ... clinical operations team to help ensure timely facilitation ...
(Date:2/11/2016)... REDWOOD CITY, Calif. , Feb. 11, 2016 /PRNewswire/ ... that a podium presentation will be made at the ... Burn and Wound Care Symposium, which is being ... . This international conference covers the latest advancements in ... endorsed by the American Burn Association, Australian-New Zealand Burns ...
Breaking Medicine Technology: